Trefoil factor 1 inhibits the development of esophageal adenocarcinoma from Barrett's epithelium.
Journal
Laboratory investigation; a journal of technical methods and pathology
ISSN: 1530-0307
Titre abrégé: Lab Invest
Pays: United States
ID NLM: 0376617
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
22
05
2021
accepted:
14
02
2022
revised:
05
02
2022
pubmed:
14
3
2022
medline:
27
7
2022
entrez:
13
3
2022
Statut:
ppublish
Résumé
Trefoil factor family 1 (TFF1) is one of three members of the trefoil factor family that are abundantly expressed in the gastrointestinal mucosal epithelium. Recent studies have shown that TFF1 acts as a tumor suppressor in gastric, pancreatic and hepatocellular carcinogenesis; however, little is known about its function in esophageal carcinogenesis, especially in esophageal adenocarcinoma (EAC). Barrett's epithelium is the metaplastic columnar epithelium of the esophagus and a known premalignant lesion of EAC. To investigate the role of TFF1 in EAC development, a mouse model of Barrett's epithelium was employed, and human specimens of EAC were assessed by immunohistochemistry (IHC) and methylation-specific PCR. Wild-type (WT) mice underwent gastrojejunostomy on the forestomach, resulting in the development of Barrett's epithelium-like (BE-like) epithelium adjacent to the anastomotic site. BE-like epithelium in these mice expressed TFF1, indicating the association of TFF1 with esophageal adenocarcinoma. TFF1-knockout (TFF1KO) mice underwent the same procedure as well, revealing that a deficiency in TFF1 resulted in the development of adenocarcinoma in the anastomotic site, presumably from BE-like epithelium. IHC of human samples revealed strong TFF1 expression in Barrett's epithelium, which was lost in some EACs, confirming the association between TFF1 and EAC development. Aberrant DNA hypermethylation in TFF1 promoter lesions was detected in TFF1-negative human EAC samples, further confirming not only the role of TFF1 in EAC but also the underlying mechanisms of TFF1 regulation. In addition, IHC revealed the nuclear translocation of β-catenin in human and mouse EAC, suggesting that activation of the Wnt/β-catenin pathway was induced by the loss of TFF1. In conclusion, these results indicate that TFF1 functions as a tumor suppressor to inhibit the development of esophageal carcinogenesis from Barrett's epithelium.
Identifiants
pubmed: 35279702
doi: 10.1038/s41374-022-00771-1
pii: S0023-6837(22)00098-8
doi:
Substances chimiques
TFF1 protein, human
0
Tff1 protein, mouse
0
Trefoil Factor-1
0
beta Catenin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
885-895Informations de copyright
© 2022. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.
Références
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
doi: 10.3322/caac.21492
Thrift, A. P. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 41, 88–95 (2016).
doi: 10.1016/j.canep.2016.01.013
Coleman, H. G., Xie, S. H. & Lagergren, J. The epidemiology of esophageal adenocarcinoma. Gastroenterology 154, 390–405 (2018).
doi: 10.1053/j.gastro.2017.07.046
Thrift, A. P. Barrett’s esophagus and esophageal adenocarcinoma: how common are they really? Dig. Dis. Sci. 63, 1988–1996 (2018).
doi: 10.1007/s10620-018-5068-6
Domper Arnal, M. J., Ferrández Arenas, Á., & Lanas Arbeloa, A. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J. Gastroenterol. 21, 7933–7943 (2015).
doi: 10.3748/wjg.v21.i26.7933
Sun, D. et al. Bile acids but not acidic acids induce Barrett’s esophagus. Int. J. Clin. Exp. Pathol. 8, 1384–1392 (2015).
pubmed: 25973022
pmcid: 4396229
Kumarasinghe, M. P., Armstrong, M., Foo, J. & Raftopoulos, S. C. The modern management of Barrett’s oesophagus and related neoplasia: role of pathology. Histopathology 78, 18–38 (2021).
doi: 10.1111/his.14285
Oh, D. S. et al. Validation of a rodent model of Barrett’s esophagus using quantitative gene expression profiling. Surg. Endosc. 23, 1346–1352 (2009).
doi: 10.1007/s00464-008-0169-5
Miyashita, T. et al. Duodenal juice stimulates oesophageal stem cells to induce Barrett’s oesophagus and oesophageal adenocarcinoma in rats. Oncol. Rep. 15, 1469–1475 (2006).
pubmed: 16685381
Su, Y. et al. Phenotype of columnar-lined esophagus in rats with esophagogastroduodenal anastomosis: similarity to human Barrett’s esophagus. Lab. Investig. 84, 753–765 (2004).
doi: 10.1038/labinvest.3700079
Madsen, J., Nielsen, O., Tornøe, I., Thim, L. & Holmskov, U. Tissue localization of human trefoil factors 1, 2, and 3. J. Histochem. Cytochem. 55, 505–513 (2007).
doi: 10.1369/jhc.6A7100.2007
Ren, J. L., Luo, J. Y., Lu, Y. P., Wang, L. & Shi, H. X. Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. World J. Gastroenterol. 11, 2674–2677 (2005).
doi: 10.3748/wjg.v11.i17.2674
Yamaguchi, J. et al. Pancreatic duct glands (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair. Stem Cell Res. 15, 190–202 (2015).
doi: 10.1016/j.scr.2015.05.006
Hayashi, Y. et al. Loss of trefoil factor 1 inhibits biliary regeneration but accelerates the hepatic differentiation of progenitor cells in mice. Biochem. Biophys. Res. Commun. 506, 12–19 (2018).
doi: 10.1016/j.bbrc.2018.10.023
Lefebvre, O. et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274, 259–262 (1996).
doi: 10.1126/science.274.5285.259
Yamaguchi, J. et al. Trefoil factor 1 inhibits epithelial-mesenchymal transition of pancreatic intraepithelial neoplasm. J. Clin. Investig. 128, 3619–3629 (2018).
doi: 10.1172/JCI97755
Ochiai, Y. et al. Trefoil factor family 1 inhibits the development of hepatocellular carcinoma by regulating β-catenin activation. Hepatology 72, 503–517 (2020).
doi: 10.1002/hep.31039
Gonzaga, I. M. et al. TFF1 hypermethylation and decreased expression in esophageal squamous cell carcinoma and histologically normal tumor surrounding esophageal cells. Clin. Epigenetics 9, 130 (2017).
doi: 10.1186/s13148-017-0429-0
Dunn, L. J., Jankowski, J. A. & Griffin, S. M. Trefoil factor expression in a human model of the early stages of Barrett’s esophagus. Dig. Dis. Sci. 60, 1187–1194 (2015).
doi: 10.1007/s10620-014-3440-8
Fox, C. A. et al. Altered expression of TFF-1 and CES-2 in Barrett’s esophagus and associated adenocarcinomas. Neoplasia 7, 407–416 (2005).
doi: 10.1593/neo.04715
Feng, G. et al. DNA methylation of trefoil factor 1 (TFF1) is associated with the tumorigenesis of gastric carcinoma. Mol. Med. Rep. 9, 109–117 (2014).
doi: 10.3892/mmr.2013.1772
Soutto, M. et al. Loss of TFF1 promotes Helicobacter pylori-induced β-catenin activation and gastric tumorigenesis. Oncotarget 6, 17911–17922 (2015).
doi: 10.18632/oncotarget.3772
Terabe, F. et al. Columnar metaplasia in three types of surgical mouse models of esophageal reflux. Cell. Mol. Gastroenterol. Hepatol. 4, 115–123 (2017).
doi: 10.1016/j.jcmgh.2017.03.009
Hao, J., Liu, B., Yang, C. S. & Chen, X. Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice. BMC Gastroenterol. 9, 59 (2009).
doi: 10.1186/1471-230X-9-59
Xu, X., LoCicero, J. 3rd, Macri, E., Loda, M. & Ellis, F. H. Jr. Barrett’s esophagus and associated adenocarcinoma in a mouse surgical model. J. Surg. Res. 88, 120–124 (2000).
doi: 10.1006/jsre.1999.5774
Mukaisho, K. I. et al. Barretts’s carcinogenesis. Pathol. Int. 69, 319–330 (2019).
pubmed: 31290583
pmcid: 6851828
Jiang, M. et al. Transitional basal cells at the squamous-columnar junction generate Barrett’s oesophagus. Nature 550, 529–533 (2017).
doi: 10.1038/nature24269
Kanai, S., Mukaisho, K. I., Yoshida, S., Taniura, N. & Sugihara, H. Host factors influence Barrett’s carcinogenesis: findings from a mouse gastroduodenal reflux model. Esophagus 16, 264–271 (2019).
doi: 10.1007/s10388-019-00660-5
Shang, S., Hua, F. & Hu, Z. W. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8, 33972–33989 (2017).
doi: 10.18632/oncotarget.15687
Moyes, L. H. et al. Activation of Wnt signalling promotes development of dysplasia in Barrett’s oesophagus. J. Pathol. 228, 99–112 (2012).
doi: 10.1002/path.4058
Bian, Y. S., Osterheld, M. C., Bosman, F. T., Fontolliet, C. & Benhattar, J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am. J. Clin. Pathol. 114, 583–590 (2000).
doi: 10.1309/3QLC-5MF1-JYXU-A5XX
Soutto, M. et al. Activation of β-catenin signalling by TFF1 loss promotes cell proliferation and gastric tumorigenesis. Gut 64, 1028–1039 (2015).
doi: 10.1136/gutjnl-2014-307191
Paterson, A. L., Gehrung, M., Fitzgerald, R. C. & O’Donovan, M. Role of TFF3 as an adjunct in the diagnosis of Barrett’s esophagus using a minimally invasive esophageal sampling device-The Cytosponge(TM). Diagn. Cytopathol. 48, 253–264 (2020).
doi: 10.1002/dc.24354